The Science and Art of De-risking Cancer Drug Development | Talking Precision Medicine #35

from Talking Precision Medicine · host Genialis

In this episode Genialis CEO Rafael Rosengarten sat down with Dr. Carolina Haefliger, head of translational medicine at Debiopharm, the privately held Swiss biopharma company focused on oncology drug development. They talked about de-risking promising new cancer drugs, and what it takes from the science to the team to the technologies. Episode 35 links: Visit ⁠⁠⁠TPM E35⁠⁠⁠ for highlights and links from this episode > Learn more about Genialis™ krasID > New Genialis RNA Biomarker Accurately Predicts KRAS Outcomes in Lung Cancer Patients >

Episode metadata supplied by the publisher feed · Published Apr 12, 2024

Embed this episode

Attribution link and audio player

Ready to play

The Science and Art of De-risking Cancer Drug Development | Talking Precision Medicine #35

0:00 31:27

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Talking Precision Medicine?

This episode is 31 minutes long.

When was this Talking Precision Medicine episode published?

This episode was published on April 12, 2024.

Can I download this Talking Precision Medicine episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!